miR-10a-5p treatment increased de novo adipogenesis in gWAT and prevented HFD-induced glucose intolerance. A. qPCR analysis of miRNAs in gWAT of mice fed chow or high fat diet for 8 weeks (mean ± S.E.M, t-tests, n = 4 per group,*p < 0.05, ***p < 0.001). B. qPCR analysis of miR-10a-5p in ATM isolated from gWAT of mice fed chow or high fat diet for 8 weeks. Stromovascular cells were pooled from 4 mice per sample and biological triplicates (n = 3) per condition were analyzed for qPCR. (mean ± S.E.M, t-tests, *p < 0.05). C. miR-10a-5p mimic injection and HFD feeding. D. qPCR analysis of miRNA in gWAT of mice fed with HFD for 8 weeks and treated with miR-10a-5p mimic or negative controls (NC). E. Body weight. F. Fat mass analysis. G. H/E staining of gWAT. H. Adipocyte size analysis of H/E stained paraffin sections of gWAT. I. Adipose cellularity analysis. J. Crown-like structure (CLS) analysis of H/E stained paraffin sections of gWAT. CLS were defined as circular regions with continuous rim of myeloid cells. K. qPCR analysis of gWAT of mice fed with HFD for 8 weeks and treated with miR-10a-5p mimics or NC. L. Plin1 and tdTomato staining in paraffin sections of gWAT of tamoxifen-induced Pdgfra-CreER/tdTomato reporter mice fed with HFD and treated with miR-10a-5p mimics or NC. M. Quantification of Plin1+tdTomato + adipocytes (n = 4, t-test, **p < 0.01) N. Glucose tolerance test and quantification. (negative controls: N.C., mean ± S.E.M, Bonferroni posttests, n = 4–5 per group,***p < 0.001; two-way ANOVA: p values indicate significance of miR-10a-5p treatment effects).